---
title: Developing a Culturally Adapted Intervention for Latino Youth Transitioning to Adulthood
nct_id: NCT06107972
overall_status: ACTIVE_NOT_RECRUITING
phase: NA
sponsor: The University of Texas Health Science Center, Houston
study_type: INTERVENTIONAL
primary_condition: Autism Spectrum Disorder
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06107972.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06107972"
ct_last_update_post_date: 2025-08-27
last_seen_at: "2026-05-12T06:26:21.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Developing a Culturally Adapted Intervention for Latino Youth Transitioning to Adulthood

**NCT ID:** [NCT06107972](https://clinicaltrials.gov/study/NCT06107972)

## Key Facts

- **Status:** ACTIVE_NOT_RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 56
- **Lead Sponsor:** The University of Texas Health Science Center, Houston
- **Collaborators:** UTHealth Houston Seed Grant and Autism Speaks Fellowship
- **Conditions:** Autism Spectrum Disorder
- **Start Date:** 2024-04-01
- **Completion Date:** 2025-12-31
- **CT.gov Last Update:** 2025-08-27

## Brief Summary

The purpose of this study is to evaluate the acceptability, feasibility (e.g., satisfaction, completion rate, barriers to recruitment, treatment fidelity) of the culturally refined Launching! to Adulthood (¡Iniciando! la Adultez) program, to test for a preliminary signal of effect between baseline and post-treatment for the Launching! to Adulthood (¡Iniciando! la Adultez) program and to identify preliminary neural mechanisms of action, including biomarkers of brain structure and connectivity, in terms of treatment response for 15 Latino young adults participating in the ¡Iniciando! therapy program.

## Detailed Description

The Launching! to Adulthood (¡Iniciando! la Adultez) program uses a culturally sensitive therapy program that was translated into Spanish to help Latino young adults with Autism Spectrum Disorder (ASD) who are transitioning to adulthood (18-25 years old) and their parents. The program aims to make the transition to adulthood easier for young adults and their families, and it includes specific cultural values of Latino young adults and their family members. The ¡Iniciando! la adultez program helps autistic young adults manage mental health needs like depression and anxiety and also addresses several areas impacting transition, including mental health barriers, executive functioning, and motivation. The ¡Iniciando! program also helps parents manage their own needs and addresses several areas, including psychoeducation and mental health.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 25 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* confirmed case of ASD
* a score of \>14 on the Social Communication Questionnaire-Lifetime (SCQ-L110) completed with the mother or father
* meet DSM-5 criteria for ASD based on a Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 ASD symptom checklist
* previous diagnosis of ASD from a licensed mental health or medical professional
* speak English
* have a parent willing to participate
* score \>85 on verbal intelligence quotient (IQ) on the Kaufman Brief Intelligence Test (KBIT-2)

Exclusion Criteria:

* history of a psychotic disorder or current psychotic symptoms
* suicidal ideation with intent or plan
* current alcohol or other substance use disorder rated severe
* concurrent enrollment in another clinical trial for autism spectrum disorder
* expression of unwillingness to complete study procedures
* For fMRI, unable to undergo fMRI scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips, or other implanted metal parts) or claustrophobic to the scanner.
```

## Arms

- **Launching! to Adulthood (¡Iniciando! la Adultez) program** (EXPERIMENTAL)

## Interventions

- **Launching! to Adulthood (¡Iniciando! la Adultez) program** (BEHAVIORAL) — The program includes cognitive behavioral and acceptance and commitment therapy, with a focus on developing goals during the transition to adulthood through a values framework. After a combined (parents and young adults) 90-minute introductory group meeting in-person, parents and the transition-aged young adults with ASD attend 9 separate, 90-minute weekly group telehealth meetings. Additionally, young adults have weekly personal coaching meetings for 30-minutes to discuss progress toward goals and barriers encountered. Leaders teach transition-aged young adult's skills through various social activities, as well as other skills (e.g., emotion regulation, cognitive diffusion) to help overcome barriers towards their goals. The treatment targets three core factors (i.e., mental health conditions, social skills, and coping with and adapting to stress). Leaders teach parents new parenting skills, knowledge of ASD, and readiness to support their young adult's transition to independent life.

## Primary Outcomes

- **Change in adaptive behavior as assessed by the Adaptive Behaviour Assessment System, Third Edition** _(time frame: baseline, mid-treatment (5 weeks after baseline) , post-treatment (12 weeks after baseline), 3 month follow up, 6 month follow up)_ — This is a 239 item questionnaire and each is scored from 0(is not able to do this behavior) to 3 \[(always able to do this behavior)(or almost always)\] a higher number indicating better outcome
- **Change in Quality of life as assessed by the Autism Spectrum Quality of Life (ASQoL) questionnaire** _(time frame: baseline, mid-treatment (5 weeks after baseline) , post-treatment (12 weeks after baseline), 3 month follow up, 6 month follow up)_ — This is a 9 item questionnaire. Questions 1-5 and 9 are each scored from 1(not at all) to 5(totally) a higher number indicating better outcome and questions 6-8 are reverse scored from 5(never) to 1(always) a higher score indicating worse outcome
- **Change in Anxiety as assessed by the Generalized Anxiety Disorder-7 (GAD7)** _(time frame: baseline, mid-treatment(5 weeks after baseline) , post-treatment (12 weeks after baseline), 3 month follow up, 6 month follow up)_ — This is a 7 item questionnaire and each is scored from 0(not at all) to 4(nearly every day) for a maximum score of 21 , higher score indicating more anxiety
- **Change in depression as assessed by the Patient Health Questionnaire (PHQ-9)** _(time frame: baseline, mid-treatment(5 weeks after baseline) , post-treatment (12 weeks after baseline), 3 month follow up, 6 month follow up)_ — This is a 9 item questionnaire and each is scored from 0(not at all) to 3(nearly every day) for a maximum score of 27, higher number indicating worse outcome

## Secondary Outcomes

- **Change in caregiver burden as assessed by the Rapid Screen for Caregiver Burden (CBI)** _(time frame: baseline, mid treatment (5 weeks after baseline) , post-treatment (12 weeks after baseline), 3 month follow up, 6 month follow up)_
- **Change in efficacy of coping with life's challenges as assessed by the Coping Self-Efficacy Scale (CSES)** _(time frame: baseline, mid treatment (5 weeks after baseline) , post-treatment (12 weeks after baseline),3 month follow up, 6 month follow up)_
- **Change in stress as assessed by the Riverside Acculturation Stress Inventory (RASI)** _(time frame: baseline, mid treatment (5 weeks after baseline) , post-treatment (12 weeks after baseline), 3 month follow up, 6 month follow up)_
- **Change in goal attainment Goal Attainment Scaling (GAS)** _(time frame: week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 11, week 12)_

## Locations (1)

- The University of Texas Health Science Center at Houston, Houston, Texas, United States

## Recent Field Changes (last 30 days)

- `armsInterventions.arms` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.the university of texas health science center at houston|houston|texas|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06107972.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06107972*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*